Analyzing the Quarter 3 financial results of atai Life Sciences (Nasdaq: ATAI), Compass Pathways (Nasdaq: CMPS), MindMed (Nasdaq: MNMD) and Cybin (NYSE: CYBN).

It’s earning season! In this episode we compare and contrast the financials of the four biggest companies in the psychedelic medicines space, atai, Compass Pathways, MindMed and CYBIN. All four released their Q3 financials in the past week. All four are the biggest psychedelic stocks
We also look at some of the highlights of the past quarter for each company, and do some rough back of the napkin math to determine when they will need to raise more capital.

Atai Life Sciences (atai stock) is the best financed company, and had a very eventful quarter. They started clinical trials studying r-ketamine, ibogaine, a schizophrenia drug and more.
Compass Pathways (CMPS stock), the next best financed psychedelics company, released the results of their long awaited Comp 360 phase 2b clinical trial, testing treating Treatment-Resistant Depression with psilocybin. They also announced a new trial using comp 360 to treat PTSD, hired the famous Hamilton Morris, and acquired an IP portfolio of novel medicines.

MindMed (MNMD Stock) had a quieter quarter, though it was still impressive. Despite having over a hundred million dollars in the bank, since they are spending so much on their million projects, they will likely have to raise capital through dilution within a year. Their work with LSD, 18-MC Psilocybin and more continues in the background, but this quarter was all about hiring talent.

Cybin (CYBN stock) is in a bigger cash crunch, only having enough capital for roughly a year. This means they will almost certainly be raising capital soon. Despite this, they had a great quarter and announced that their lead drug candidate CYB-003, a modified version of psilocybin, shows great promise in animal models.

Links:
Atai: https://www.atai.life/2021/11/05/atai-life-sciences-reports-third-quarter-2021-financial-results-and-corporate-update/
Compass Pathways: https://compasspathways.com/financial-results-and-business-highlights-for-the-third-quarter-2021/

MindMed:
https://www.prnewswire.com/news-releases/mindmed-announces-financial-results-for-the-third-quarter-2021-and-business-highlights-cash-balance-of-145-9-usd-185-4-cad-to-execute-on-diverse-clinical-pipeline-301423844.html
Cybin:

https://www.businesswire.com/news/home/20211115005552/en/Cybin-Inc.-Reports-its-Second-Quarter-Financial-Results-and-Recent-Business-Highlights

Enjoy the episode!
Follow us on social media!
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
James’ Twitter: @Psy_Invest
Maria’s Twitter (Producer & Editor): @Psy_Holy

Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Music from:
www.bensound.com
Video editing: @themyaholy

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#ataiLifeSciences #MindMed #Cybin

Similar Posts

Numinus Acquires Novamind: What Does This Mean for the Psychedelic Industry? | NUMI, NM

Numinus Acquires Novamind: What Does This Mean for the Psychedelic Industry? | NUMI, NM

Listen, Videos

Numinus Acquiring Novamind in First Major Psychedelics Merger

Get your 20%-off tickets to the Catalyst Psychedelics Summit in Kingston Ontario, May 20th-23rd: www.eventbrite.ca/e/153409882087/?discount=SPOTLIGHT20

Not only will this be your chance to meet me, but also the legendary Paul Stamets!

Join our Newsletter (scroll to the bottom of the page and sign up): https://psychedelicspotlight.com/psyc…

Follow us on Twitter:
James: @Psy_Invest
Maria: @psy_holy
The Psychedelic Investor: @PsycInvestor
Psychedelic Spotlight: @PsycSpotlight

Follow us on Instagram:
@thepsychedelicinvestor
@psycspotlight

To learn more about the emerging psychedelic industry, visit:
https://psychedelicspotlight.com/

Back to Numinus

This acquisition will make Numinus the psychedelic medicines company with the highest revenue, though of course there is still a long road to profitability.

Psychedelic stock investors woke up to some major news today: Numinus Wellness (TSX: NUMI) (OTCQX: NUMIF) announced that they are acquiring Novamind Inc. (CSE: NM) (OTCQB: NVMDF).

The acquisition will be done in stock, and shareholders of Novamind will receive 0.84 of a common share of Numinus per Novamind share held, implying an offer price of $0.44 per Novamind share. This means Numinus is offering a premium of 51% to Novamind shareholders, based on the 20-day volume-weighted average price of their stock. When the transaction is completed, Novamind shareholders will own around 18% of Numinus.

If you currently hold Novamind stock, you do not need to do anything. When the transaction is finalized, each Novamind share you own will automatically be transformed into 0.84 of a Numinus share.

#Numinus #NovaMind #psychedelicStocks

Cathie Wood and ARK Invest Buy a Psychedelic Stock!!! | $ARKG | Initial Reaction 🍄🍾

Cathie Wood and ARK Invest Buy a Psychedelic Stock!!! | $ARKG | Initial Reaction 🍄🍾

Listen, Videos

GUYS. IT HAPPENED. Cathie Wood and ARK Invest have invested in a Psychedelic Stock! Specifically, ARKG, or the ARK Genomic Revolution ETF have purchased atai Life Sciences (Nasdaq: atai)!

Follow us on Twitter:
@Psy_Invest
@psy_holy
@PsycSpotlight

Follow us on Instagram:
@psycbiz
@psycspotlight

To learn more about the emerging psychedelic industry, visit:
https://psychedelicspotlight.com/

Last year, the Psychedelic Investor and the Reddit Page “ShroomStocks” managed to get the question of “would you ever invest in Psychedelic Stocks” asked to Cathie Wood of ARK Invest, and her answer was a dismissive NO. She said that ARK did not invest in binary stocks, though Kevin O’Leary, who was on the same panel disagreed.

Well, it seems that time (and maybe Kevin O’Leary) have changed her mind. On Wednesday, February 9th, it was revealed that the Ark Genomic Revolution ETF, ticker symbol ARKG, had purchased 83,278 shares of ATAI.

And while this only represents 0.01% of that fund’s total holdings, it does represent a big moment for the entire psychedelics industry. For better or worse, Cathie Wood has a huge voice among investors who like growth stocks, and next-generation technology stocks, which psychedelic stocks definitely represent.

This will likely put more focus, not only on atai, but the entire psychedelics sector. I would not be surprised if companies such as MindMed (MMEDF) and Cybin (CYBN) also benefit from this. Perhaps, in the future, Ark will also buy these companies.

Hopefully, this is but an opening position, and ARKG continues to buy psychedelic stocks such as atai and MindMed. Ideally, I would also like to see the flagship ETF, ARKK, also invest in psychedelic Stocks.

#CathieWood #ARKG #PsychedelicStocks